As moms, we want to do everything we can to help keep our little ones healthy, but there are some things that, despite your best efforts, can be unpredictable, like respiratory syncytial virus (#RSV). #SanofiSponsored When I had Hughes in 2020, there was so much buzz around RSV and taking all the available precautions at the time to help protect babies. While RSV symptoms are often minor and cold-like, serious RSV lung infection is the leading cause of hospitalization for babies under one. Today with baby Finn, I’m relieved to know that there’s finally an extra layer of protection available for babies. Beyfortus® (nirsevimab-alip) 50mg and 100mg Injection is a preventative antibody that helps provide babies with the protection against serious RSV lung infection they lack. I attended the Joining BeyForces Brunch hosted by @ShawnJohnson in collaboration with Sanofi and @get_nanit, to learn more about RSV and Beyfortus. It was such a beautiful afternoon, and I always love connecting with fellow moms! I also had the opportunity to hear from fellow mamas who went through RSV experiences, which really moved me. And that’s why I’m sharing with you how important it is that new moms are educated about RSV, especially with winter virus season about to start. Now is the time for expectant and new parents to talk to their OBGYN or pediatrician about Beyfortus and visit Beyfortus.com to learn more. #BeforeRSV Beyfortus is a prescription medicine used to help prevent a serious lung disease caused by RSV in newborns and babies under 1 born during or entering their first RSV season, and children up to 24 months who remain at risk of severe RSV disease through their second RSV season. Beyfortus may not protect all children. IMPORTANT SAFETY INFORMATION Your child should not take Beyfortus if your child has a history of serious allergic reactions to nirsevimab-alip or any of the ingredients in Beyfortus. Please see full Important Safety Information at the end of this post. Please find link to full Prescribing Information including Patient Information at @beyfortus_nirsevimab_alip For U.S. audiences only.